Davis Polk & Wardwell LLP is a global law firm headquartered in New York. It maintains offices in key business centers including Los Angeles, London, Hong Kong, Tokyo, and Brussels. The firm advises on corporate transactions, mergers and acquisitions, capital markets, and regulatory matters across multiple industries.
Established in 1849, Davis Polk serves leading companies and financial institutions worldwide.
Also known as Davis Polk & Wardwell.
Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.
